TNF
ENSG00000232810
Target class
Secreted protein
Chromosome
6
Approved drugs
5
Clinical candidates (approved and in development)
15
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- Yes
- Target name
- TNF
- Gene name
- Tumor necrosis factor
- Gene symbol
- TNF
- Previous gene symbols
- TNFA
- Protein name
- Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]
- TNFSF2
- DIF
- TNF-alpha
- Gene biotype
- Protein coding
- Gene family
- Tumor necrosis factor superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 8
- Highest tissue expression
- 133.01
- Tissue specificity (Gini)
- 0.908
- Tissue specificity (tau)
- 0.995
- KEGG gene identifiers
- hsa:7124
- Protein interaction confidence
- 0.830395
- Protein interaction partners
- 380
- R-HSA-381340
- R-HSA-5357786
- R-HSA-5357905
- R-HSA-5357956
- R-HSA-5626978
- R-HSA-5668541
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-75893
- R-HSA-9942503
- End position
- 31578336
- Start position
- 31575565
- Chromosome
- 6
- Strand
- Forward
- Cell membrane
- Single-pass type II membrane protein .
- SUBCELLULAR LOCATION: [Tumor necrosis factor, membrane form]: Membrane
- Single-pass type II membrane protein.
- SUBCELLULAR LOCATION: [Tumor necrosis factor, soluble form]: Secreted .
- SUBCELLULAR LOCATION: [C-domain 1]: Secreted.
- SUBCELLULAR LOCATION: [C-domain 2]: Secreted.
- PubMed 16829952
- PubMed 23552949
- Tissue specificity (tau)
- 0.994976
- Expression inequality (Gini)
- 0.907627
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 133.01
- Spleen
- 8.96
- Whole Blood
- 4.57
- Lung
- 2.68
- Small Intestine - Terminal Ileum
- 2.02
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes133.01
- Spleen8.96
- Whole Blood4.57
- Lung2.68
- Small Intestine - Terminal Ileum2.02
- Skin - Not Sun Exposed (Suprapubic)1.68
- Skin - Sun Exposed (Lower leg)1.23
- Adipose - Visceral (Omentum)1.06
- Kidney - Medulla0.86
- Kidney - Cortex0.86
- Colon - Transverse0.76
- Adrenal Gland0.74
- Esophagus - Mucosa0.7
- Artery - Coronary0.54
- Artery - Aorta0.54
- Breast - Mammary Tissue0.52
- Colon - Sigmoid0.5
- Fallopian Tube0.45
- Heart - Left Ventricle0.43
- Esophagus - Muscularis0.4
- Stomach0.39
- Minor Salivary Gland0.35
- Heart - Atrial Appendage0.34
- Esophagus - Gastroesophageal Junction0.33
- Liver0.3
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0001819
- GO:0002439
- GO:0002719
- GO:0006954
- GO:0008625
- GO:0009615
- GO:0009651
- GO:0010573
- GO:0010628
- GO:0010629
- GO:0010744
- GO:0031334
- GO:0032715
- GO:0032722
- GO:0032731
- GO:0032755
- GO:0032757
- GO:0033209
- GO:0034116
- GO:0043065
- GO:0043068
- GO:0043122
- GO:0043123
- GO:0043243
And 53 more, listed on the interactive page.
- GO:0005576
- GO:0005886
- GO:0009986
- GO:0045121
- GO:0000976
- GO:0002020
- GO:0005125
- GO:0005164
- GO:0005515
- GO:0042802
regulation of gene expression
Studies
- cell-based: BSK_LPS_TNFa, is one of 11 assay component(s) measured or calculated from the BSK_LPS assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.
Biological samples
- umbilical vein endothelium and peripheral blood mononuclear cells, primary cell co-culture
Evidence source
Related records
Trials (1,601)
- "Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
- "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"
- 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
- 16.0040 Ankylosing Spondylitis Study
- 2 Regimens of Lactulose for Colonoscopy Preparation in Adults
- 3D Evaluation of Postoperative Edema After Third Molar Surgery
- A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)
- A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
- A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis
- A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy
- A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)
- A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit
- A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
- A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
- A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
- A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
- A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
- A Clinical Study With Adalimumab Biosimilar
- A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
- A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma
Drugs (15)
- ABBV-3373 TNF-alpha binding agent
- Adalimumab TNF-alpha inhibitor
- Afelimomab TNF-alpha inhibitor
- AZ9773 TNF-alpha inhibitor
- Certolizumab pegol TNF-alpha inhibitor
- Etanercept TNF-alpha inhibitor
- Golimumab TNF-alpha inhibitor
- Infliximab TNF-alpha inhibitor
- Lenercept TNF-alpha inhibitor
- Nerelimomab TNF-alpha inhibitor
- Onercept TNF-alpha inhibitor
- Ozoralizumab TNF-alpha inhibitor
- Pegsunercept TNF-alpha inhibitor
- Placulumab TNF-alpha inhibitor
- Remtolumab TNF-alpha inhibitor